September 2021

Celyad Oncology Announces September 2021 Conferences Schedule

MONT-SAINT-GUIBERT, Belgium, Sept. 01, 2021 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for more...

Update: Acasti Pharma CEO to Present at Microcap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 18th
May 16, 2022
LAVAL, QC / ACCESSWIRE / May 16, 2022 / Acasti Pharma Inc. ("Acasti" or the "Company") (Nasdaq:ACST) and (TSX-V:ACST), today announced that Jan D'Alvise, Chief Executive Officer, has been invited to more...
36 of the Best Ideas Companies to Present at the Spring into Action – Best Ideas Investor Conference on May 16th – 20th, 2022
May 16, 2022
RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th - 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public more...
Adial Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results
May 16, 2022
Nears completion of ONWARD™ Phase 3 pivotal trial of AD04 for the treatment of Alcohol Use Disorder; on track to report Phase 3 results in the current quarter Ended first quarter w more...
CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 16, 2022
CNS Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update PR Newswire Recent approvals of potentially pivotal more...
Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy
May 16, 2022
BOSTON and JERUSALEM, May 16, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the more...
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update
May 16, 2022
NORCROSS, Ga., May 16, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported more...